JPRN-jRCT2033230284招募中Unknown
ong-term observational study of Gene Therapy for Sporadic ALS
Morita Mitsuya0 个研究点目标入组 6 人开始时间: 2023年8月9日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who enrolled in the Phase I/II Study of Gene Therapy for Sporadic ALS, and who completed or discontinued the study.
排除标准
- •-Patients who are judged by the investigator or subinvestigator to be inappropriate to participate in this study.
研究者
相似试验
招募中
不适用
ong-term observational study of Gene Therapy for AADC deficiencyAromatic L-amino acid decarboxylase deficiencyJPRN-jRCT2033220245Yamagata Takanori1
招募中
Unknown
ong-term observational study of Gene Therapy for Parkinson's diseaseParkinson's diseaseJPRN-jRCT2033220367akajima Takeshi12
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseMedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersSickle Cell DiseaseEUCTR2019-000331-63-FRbluebird bio, Inc.35
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseSickle Cell DiseaseEUCTR2019-000331-63-NLbluebird bio, Inc.35
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseMedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersSickle Cell DiseaseEUCTR2019-000331-63-ITBLUEBIRD BIO, INC.35